When Emmanuel Obeng-Dankwa is worried about making rent on his New York City apartment, he sometimes holds off on filling his blood pressure medication. 

“If there’s no money, I prefer to skip the medication to being homeless,” said Obeng-Dankwa, a 58-year-old security guard. 

He is among a majority of adults in the U.S. who say that health care is not handled well in the country, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.

The poll reveals that public satisfaction with the U.S. health care system is remarkably low, with fewer than half of Americans saying it is generally handled well. Only 12% say it is handled extremely or very well. Americans have similar views about health care for older adults. 

Overall, the public gives even lower marks for how prescription drug costs, the quality of care at nursing homes and mental health care are being handled, with just 6% or less saying those health services are done very well in the country. 

“Navigating the American health care system is exceedingly frustrating,” said A. Mark Fendrick, the director of the University of Michigan Center for Value-Based Insurance Design. “The COVID pandemic has only made it worse.” 

More than two years after the pandemic’s start, health care worker burnout and staffing shortages are plaguing hospitals around the country. And Americans are still having trouble getting in-person medical care after health centers introduced restrictions as COVID-19 killed and sickened millions of people around the country, Fendrick said. 

In fact, the poll shows an overwhelming majority of Americans, nearly 8 in 10, say they are at least moderately concerned about getting access to quality health care when they need it.

Black and Hispanic adults in particular are resoundingly worried about health care access, with nearly 6 in 10 saying they are very or extremely concerned about getting good care. Fewer than half of white adults, 44%, expressed the same level of worry. 

Racial disparities have long troubled America’s health care system. They have been abundantly clear during the COVID-19 pandemic, with Black and Hispanic people dying disproportionately from the virus. Black and Hispanic men also make up a disproportionately high rate of recent monkeypox infections.

Fifty-three percent of women said they are extremely or very concerned about obtaining quality care, compared to 42% of men. 

While Americans are united in their dissatisfaction with the health care system, that agreement dissolves when it comes to solutions to fix it. 

About two-thirds of adults think it is the federal government’s responsibility to make sure all Americans have health care coverage, with adults ages 18 to 49 more likely than those over 50 to hold that view. The percentage of people who believe health care coverage is a government responsibility has risen in recent years, ticking up from 57% in 2019 and 62% in 2017. 

Still, there’s not consensus on how that coverage might be delivered. 

About 4 in 10 Americans say they support a single-payer health care system that would require Americans to get their health insurance from a government plan. More, 58%, say they favor a government health insurance plan that anyone can purchase. 

There also is broad support for policies that would help Americans pay for the costs of long-term care, including a government-administered insurance plan similar to Medicare, the federal government’s health insurance for people 65 or older.

Retired nurse Pennie Wright, of Camden, Tennessee, doesn’t like the idea of a government-run health care system. 

After switching to Medicare this year, she was surprised to walk out of her annual well-woman visit, once fully covered by her private insurance plan, with a $200 bill. 

She prefers the flexibility she had on her private insurance plan. 

“I feel like we have the best health care system in the world, we have a choice of where we want to go,” Wright said. 

A majority of Americans, roughly two-thirds, were happy to see the government step in to provide free COVID-19 testing, vaccines and treatment. Roughly 2 in 10 were neutral about the government’s response. 

The government’s funding for free COVID-19 tests dried up at the beginning of the month. And while the White House says the latest batch of recommended COVID-19 boosters will be free to anyone who wants one, it doesn’t have money on hand to buy any future rounds of booster shots for every American. 

Eighty percent say they support the federal government negotiating for lower drug prices. President Joe Biden this summer signed a landmark bill into law allowing Medicare to negotiate the price of prescription drugs. The move is expected to save taxpayers as much as $100 billion over the next decade. 

“Medication costs should be low, to the minimum so that everyone can afford it,” said Obeng-Dankwa, the Bronx renter who has trouble paying for his medication. “Those who are poor should be able to get all the necessary health they need, in the same way someone who also has the money to pay for it.”
…

New York Governor Kathy Hochul declared a disaster emergency Friday in a bid to accelerate efforts to vaccinate residents against polio after the virus was detected in wastewater samples taken in four counties. 

Hochul’s executive order followed the discovery of the virus last month in samples from Long Island’s Nassau County, bordering the New York City borough of Queens. Earlier this year the virus was found in samples from Rockland, Orange and Sullivan counties, all north of the city.  

In July, the first confirmed case of polio in the United States in nearly a decade turned up in an adult in Rockland County, according to the state health department. 

“On polio, we simply cannot roll the dice,” State Health Commissioner Mary Bassett said in a statement. “If you or your child are unvaccinated or not up to date with vaccinations, the risk of paralytic disease is real.” 

Polio can cause irreversible paralysis in some cases, but it can be prevented by a vaccine first made available in 1955. While there is no known cure, three injections of the vaccine provide nearly 100% immunity. 

People of all ages are under threat, though the virus primarily affects children age 3 and younger.  

Officials urged inoculations for unvaccinated adults and children as young as 2 months, and they advised that vaccinated people receive a lifetime booster dose. 

Hochul’s declaration authorizes paramedics, midwives and pharmacists to administer polio vaccinations, among other steps, to accelerate inoculation rates. The order also directs health care providers to update the state with data on immunizations. 

The state of emergency will stay in effect until October 9. Health officials set a goal of getting 90% of residents vaccinated. 

The state health department warned that people in New York City and Rockland, Orange, Sullivan and Nassau counties are at the highest risk.  

Orange County has the lowest vaccination rate of the counties of concern with less than 59% being immunized, according to the state health department. 
…

NASA’s moon mission suffers another setback, this time delaying a test launch for at least a few weeks. Plus, a look back at the first color images of Mars, and we wish a very happy birthday to a TV space pioneer. VOA’s Arash Arabasadi brings us The Week in Space.  
…

The introduction of a nationwide mental health hotline has increased the numbers of people calling for help in the United States and the need for more counselors to answer their calls. For VOA, Svitlana Prystynska has this story from the Western state of Colorado. Camera – Vladimir Petruniv.
…

The World Health Organization is warning of a resurgence of deadly meningitis in Africa because COVID-19 has disrupted lifesaving vaccination campaigns.

The near elimination of the deadly form of meningitis type A in Africa is one of the continent’s biggest health success stories. Over the last 12 years, about 350 million Africans have received a single dose of MenAfriVac, a vaccine designed specifically for the African meningitis belt.  

The WHO regional director for Africa, Matshidiso Moeti, said not a single case of meningitis Group A has been reported on the continent in the past five years.

“Now, however, the COVID-19 pandemic has delayed vaccination campaigns targeting more than 50 million African children, raising the risk that these gains will be reversed,” she said. “In addition, major outbreaks caused by meningitis Group C have been recorded in seven of the African Sub-Saharan meningitis belt countries in the past nine years.”

Moeti noted a four-month outbreak last year in the Democratic Republic of Congo claimed more than 200 lives.  

Francois Marc Laforce, director of technical services for the Serum Institute of India, played a pivotal role in the development of the MenAfriVac vaccine at the Serum Institute nearly two decades ago. He said that besides meningitis Group C, Africa currently is contending with residual outbreaks of other forms of meningitis.

“A new vaccine again specifically designed for the African meningitis belt will, hopefully, be prequalified later this year or early next year,” he said. But this vaccine holds the promise of finishing what MenAfriVac began, such that Africa may be the first continent to be free of meningitis epidemics.”  

Meningitis is caused by inflammation of the membranes that surround the brain and spinal cord. Acute bacterial meningitis can cause death within 24 hours.  Young children are most at risk. About half the cases and deaths occur in children under age five.

The WHO launched a new strategy Thursday to defeat bacterial meningitis in the African region by 2030. The plan calls for shoring up diagnosis, surveillance, care, and vaccination. The WHO estimates $1.5 billion will be needed to implement the plan between now and 2030.
…

A new malaria vaccine developed by Britain’s University of Oxford is 80% effective in preventing infection, according to trial results published Thursday in The Lancet medical journal. Scientists say it represents a huge breakthrough that has the potential to save millions of lives and eventually eradicate the disease.

The vaccine, named R21/Matrix-M, had already shown encouraging trial results after three primary doses. Maintaining that immunity has always been a big challenge and the latest trial shows that a booster dose is effective, explained Professor Adrian Hill, the director of the Jenner Institute at the University of Oxford and co-author of The Lancet paper. 

“The technology has been complex to develop because we need very strong antibody responses to get protection against malaria and those antibodies, like all responses, decline over time,” Hill told VOA. 

“One of the worries was that this would be short-term protection and only last for a few months. That’s definitely not the case with the data we’re releasing today,” Hill said. “And indeed, 80% efficacy in the second year of follow up after a booster dose is really very encouraging in that respect.” 

The latest phase II trial involved 450 children between 5 and 17 months old, recruited from the Nanoro region in Burkina Faso. The results show a higher strength booster dose was 80% effective in preventing malaria infection. No serious side effects were seen. 

“This is a parasite we’re trying to vaccinate against. It’s not a virus. It’s got thousands of genes. [So it’s] complex to design a vaccine,” Hill said. “Over 100 have been in clinical trials and this looks like the best data so far. So we’re excited.” 

The Serum Institute of India, which has produced billions of doses of the Oxford-AstraZeneca COVID-19 vaccine, is producing the R21/Matrix-M malaria vaccine. It has signed an agreement to rapidly scale up production if the vaccine receives World Health Organization (WHO) approval in coming months. 

“We’re trying to do something similar with malaria, to produce a low-cost vaccine — a few dollars a dose — and to manufacture that really upscale so we can get 100 million doses or more out there as soon as possible,” Hill told VOA. 

Malaria killed an estimated 627,000 people in 2020, the most recent available data. The majority are children under five years old in sub-Saharan Africa. 

The WHO approved the first-ever malaria vaccine in October of last year, called RTS,S. But R21 may offer even greater hope, said Hill. 

“A vaccine with high efficacy like this should be able to save hundreds of thousands of lives a year and ultimately millions of lives over the next decade or so,” he said. “After we get a vaccine rolled out for that very vulnerable population, we’ll be looking at a travelers’ vaccine and then we’ll be looking at a vaccine that could actually eliminate regionally and eradicate globally this terrible disease.” 

Results from the ongoing phase III trial involving 4,800 children are due later this year and it’s hoped that mass production and rollout can begin in 2023, following WHO approval. 
…

A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group earlier this year.

The Food and Drug Administration advisers voted 7-2 that data from Amylyx Pharma warranted approval, despite hours of debate about the strength and reliability of the company’s lone study. The FDA is not required to follow the group’s advice, but its positive recommendation suggests an approval is likely later this month.

The FDA has approved only two therapies for the disease, amyotrophic lateral sclerosis, or ALS, which destroys nerve cells needed for basic functions like walking, talking and swallowing.

Patients support drug

ALS patients and their families have rallied behind Amylyx’s drug, launching an aggressive lobbying campaign and enlisting members of Congress to push the FDA to grant approval.

Despite a negative review published by FDA’s internal scientists ahead of the meeting, a majority of the outside panelists said Amylyx had presented enough evidence to suggest the drug is helping patients live longer. The same group of neurology experts narrowly voted against the drug in March, because of concerns about missing data and other issues in the company’s study.

“To deprive ALS patients of a drug that might work, it’s probably not something I would feel terribly comfortable with,” said Dr. Liana Apostolova of Indiana University’s School of Medicine, who voted for approval. “At the previous meeting it wasn’t that clear and it’s still questionable.”

Amylyx also appeared to benefit from an unusual exchange in which a company executive — at the FDA’s request — committed to pull the drug from the market if its benefits aren’t confirmed by a large, ongoing study.

The FDA has the power to force companies to pull drugs from the market, though it’s generally faster if drugmakers voluntarily take that step. In cases where companies resist removal the regulatory process can drag on for years.

New data prompts second look

Wednesday’s vote concluded a rare second meeting to review several new statistical analyses submitted by Amylyx in support of the treatment’s benefit in slowing disease and extending life.

The ALS drug review is being closely watched as an indicator of FDA’s flexibility in reviewing experimental medications for the terminally ill and its ability to withstand outside pressure.

Amylyx conducted one small, mid-stage trial of its drug that showed some benefit in slowing the disease, but it was plagued by missing data and other problems, according to FDA reviewers.

“The final result — for a single study — is borderline and not very statistically persuasive,” FDA statistician Tristan Massie told panelists.

Company says data shows drug extends life

The Cambridge, Massachusetts, company says follow-up data gathered after the study concluded showed the drug extended life. Patients who continued taking the drug survived about 10 months longer than patients who never took the drug, according to a new company analysis.

Panelists favoring the drug cited that data, along with the drug’s mild side effects, to suggest there would be little downside for patients even if it doesn’t ultimately slow ALS.

Hanging over the review is FDA’s controversial approval of the Alzheimer’s drug Aduhelm last year, which was reviewed by the same agency scientists and outside advisers.

In that case, the FDA disregarded the overwhelmingly negative vote by its outside advisers, three of whom resigned over the decision. The agency’s approval — which followed irregular meetings with drugmaker Biogen — is under investigation by Congress and federal inspectors.
…

As the world grapples with multiple climate-related disasters on different continents, a watchdog group in Washington is pressing the Biden administration to take more aggressive action to reduce emissions in the United States.

A report, issued by the liberal-leaning Revolving Door Project, outlines a wide number of actions that the group believes President Joe Biden can implement by executive action, meaning that he would not need to coax cooperation from U.S. lawmakers currently preoccupied with looming midterm elections.

Headlines this week underscore the challenges facing the planet. As the report was issued, Pakistan was suffering from catastrophic floods that have displaced tens of thousands and ravaged crops; a powerful typhoon recently dropped a meter of rain on South Korea; China is suffering its worst heat wave on record; and the western United States is gripped by a drought of historic severity.

The Environmental Protection Agency may seem like the most obvious focus of the report’s attention, and the list of steps that agency might take is indeed long. However, the report also homes in on actions available to many other federal agencies, such as the Department of Justice and the Department of Defense, that are not typically associated with climate change issues.

“Every part of the government should be thinking very much about how to consider climate in the work that they do — how to incorporate it into their existing mandates to protect their various domains, and to be thinking and acting very creatively and aggressively on this,” Max Moran, a research director at the Revolving Door Project and one of the report’s authors, told VOA.

EPA urged to act

The Environmental Protection Agency has the most expansive authority over climate-related issues in the federal government, but its enforcement capacity was significantly reduced during the Trump administration.

“The EPA can be one of the most powerful governmental actors in the United States when it is given the resources and direction to effectively implement its mandate,” the Revolving Door Project notes. “It has broad authority to police pollution and environmental degradation to minimize environmental destruction and public health impacts.”

The report urges the agency to be more aggressive in punishing corporations that violate environmental regulations, pointing out that penalties handed out by the agency often involve companies hiring their own auditors to assure future compliance or funding projects that have little to do with mitigating the damage they have caused.

As the agency works to reinvigorate its enforcement capacity, the report recommends multiple other ways in which it can step up its policing of rules regulating some of the most environmentally damaging emissions, including the powerful greenhouse gas methane.

Departments of Interior, Justice

The report notes a number of measures available to the Department of the Interior to reduce carbon emissions, one of the largest of which is capping abandoned oil and gas wells. Although old wells are not commercially viable, they still emit thousands of tons of methane into the environment every year, and capping them would greatly reduce the volume of gas that escapes.

In addition, the report calls on Interior to stop leasing federal land to energy companies for further development of fossil fuel extraction operations and to reform mining regulations to reduce damage to the environment from factors including the degradation of water sources and the runoff of dangerous chemicals.

The Department of Justice, the report argues, is insufficiently aggressive about prosecuting criminal violations of environmental laws.

“Environmental litigation is key to ensuring that companies and individuals comply with environmental laws,” it says. “Without the threat of litigation, the laws protecting ecosystems and public health are toothless.”

It notes that one government database identifies “thousands of facilities across the country with multiple significant violations” that have remained out of compliance for years without facing prosecution.

Administration shifts climate team

There is reason to believe the Biden administration is prepared to focus more on executive action than it has in the first year and a half of the president’s term. For most of that time, Biden was trying to negotiate with a balky Congress on major environmental legislation, and aggressive action by the executive branch might have made agreement more difficult to reach.

Now, however, with the passage of the Inflation Reduction Act (IRA), which included the largest investment in green energy and other climate-conscious programs in history, the likelihood of further legislation is unlikely in the near term.

Last week, Biden announced that he has hired a veteran Washington insider, John Podesta, as a senior adviser in charge of rolling out the billions in tax incentives and other programs put in place by the IRA.

At the same time, Biden announced the promotion of Ali Zaidi to national climate adviser, to replace the departing Gina McCarthy. Zaidi is a veteran of the Obama administration where, for eight years, he served in a variety of posts related to climate policy.

In a statement announcing the nomination, Biden seemed to signal that more executive action is coming.

“The Inflation Reduction Act is the biggest step forward on clean energy and climate in history, and it paves the way for additional steps we will take to meet our clean energy and climate goals,” the president said.

While the IRA earned the support of some Republicans in Congress, there is significant resistance in the GOP to greater regulation in general, and greater environmental regulation in particular. If the Biden administration does become more assertive about environmental regulation, Republicans will have little recourse in the near term. However, they are likely to use the issue to try to drive turnout in both November’s midterm elections and the 2024 presidential election.
…

Electronic cigarette maker Juul Labs has agreed to pay nearly $440 million to settle a two-year investigation by 33 U.S. states into the marketing of its high-nicotine vaping products, which have long been blamed for sparking a national surge in teen vaping.

Connecticut Attorney General William Tong announced the deal Tuesday on behalf of the states plus Puerto Rico, which joined together in 2020 to probe Juul’s early promotions and claims about the benefits of its technology as a smoking alternative.

The settlement, which includes numerous restrictions on how Juul can market its products, resolves one of the biggest legal threats facing the beleaguered company, which still faces nine separate lawsuits from other states. Additionally, Juul faces hundreds of personal lawsuits brought on behalf of teenagers and others who say they became addicted to the company’s vaping products.

The states’ investigation found that Juul marketed its e-cigarettes to underage teens with launch parties, product giveaways and ads and social media posts using youthful models, according to a statement.

“We think that this will go a long way in stemming the flow of youth vaping,” Tong said at a news conference at his Hartford office.

“I’m under no illusions and cannot claim that it will stop youth vaping,” he said. “It continues to be an epidemic. It continues to be a huge problem. But we have essentially taken a big chunk out of what was once a market leader, and by their conduct, a major offender.”

The $438.5 million will be paid out over a period of six to 10 years. Tong said Connecticut’s payment of at least $16 million will go toward vaping prevention and education efforts. Juul previously settled lawsuits in Arizona, Louisiana, North Carolina and Washington.

The settlement total amounts to about 25% of Juul’s U.S. sales of $1.9 billion last year. Tong said it was an “agreement in principle,” meaning the states will be finalizing the settlement documents over the next several weeks.

Most of the limits imposed by Tuesday’s settlement won’t immediately affect Juul, which halted use of parties, giveaways and other promotions after coming under scrutiny several several years ago.

Teen use of e-cigarettes skyrocketed after Juul’s launch in 2015, leading the U.S. Food and Drug Administration to declare an “epidemic” of underage vaping among teenagers. Health experts said the unprecedented increase risked hooking a generation of young people on nicotine.

But since 2019 Juul has mostly been in retreat, dropping all U.S. advertising and pulling its fruit and candy flavors from store shelves.

The biggest blow came earlier this summer when the FDA moved to ban all Juul e-cigarettes from the market. Juul challenged that ruling in court, and the FDA has since reopened its scientific review of the company’s technology.

The FDA review is part of a sweeping effort by regulators to bring scrutiny to the multibillion-dollar vaping industry after years of delays. The agency has authorized a handful of e-cigarettes from Juul’s competitors for adult smokers looking for a less harmful alternative.

While Juul’s early marketing focused on young, urban consumers, the company has since shifted to pitching its product as an alternative nicotine source for older smokers.

“We remain focused on our future as we fulfill our mission to transition adult smokers away from cigarettes—the number one cause of preventable death—while combating underage use,” the company said in a statement.

Juul has agreed to refrain from a host of marketing practices as part of the settlement. They include not using cartoons, paying social media influencers, depicting people under 35, advertising on billboards and public transportation and placing ads in any outlets unless 85% of their audience are adults.

The deal also includes restrictions on where Juul products may be placed in stores, age verification on all sales and limits to online and retail sales.

“These are some of the toughest mandates at any point on any industry,” Tong said, “which is incredibly important because at the end of the day this is about protecting our kids and protecting all of us from a very significant public health risk.”

Juul initially sold its high-nicotine pods in flavors like mango, mint and creme. The products became a scourge in U.S. high schools, with students vaping in bathrooms and hallways between classes.

But recent federal survey data shows that teens have been shifting away from the company. Most teens now prefer disposable e-cigarettes, some of which continue to be sold in sweet, fruity flavors.

Overall, the survey showed a drop of nearly 40% in the teen vaping rate as many kids were forced to learn from home during the pandemic. Still, federal officials cautioned about interpreting the results given they were collected online for the first time, instead of in classrooms.
…

Zimbabwe is struggling to contain a measles outbreak that has killed nearly 700 people, most of them children and young people.

Zimbabwe’s government said Tuesday thousands of people have been infected with measles since an April outbreak and 698 people have died, most of them children.

Zimbabwe’s health ministry blames some religious sects for the outbreak. It says some religious groups and traditional leaders preach against getting vaccinations.

Health authorities have since been struggling to contain the infectious viral disease, which causes a rash, cough, and high fever, and can be fatal for unvaccinated children.

“Measles is a very contagious, infectious disease that spreads when a number of unvaccinated children rises beyond critical thresholds,” said Alex Gasarira, the World Health Organization’s representative in Zimbabwe. “So, what we have in Zimbabwe right now is because the number of unvaccinated children has risen because of several factors: Community who are not comfortable to have their children vaccinated, disruption [of] vaccination services because of the recent COVID-19 pandemic.”

The rising death toll is fueling calls in Zimbabwe for mandatory shots to halt the virus, but experts says the effort has to be well organized.

“Compulsory immunization has to be well planned, and it has to cover every child in this country,” said Tinashe Mundawarara of the Zimbabwe Health Law and Policy Consortium. “That would ensure that the best interest of the child is really considered.”

Zimbabwe’s health authorities have not yet made the measles vaccination mandatory and were not immediately available for comment.

But they have been campaigning for all children between six and 15 years old to be immunized and are working with aid groups like the U.N. Children’s Fund, UNICEF, to educate those who resist.

UNICEF Zimbabwe’s Dr. Tajudeen Oyewale said his organization and others are working with the government to contain the outbreak.

“Just like [during] the COVID response, the government of Zimbabwe and partners are taking seriously the current outbreak of measles that we currently have in the country,” he said. “At present, the government has deployed rapid response team supported by UNICEF, WHO and other partners to help better track the incidents of measles. More importantly, UNICEF and our community actors are also working hand in hand to increase awareness of the measles vaccine and also help address community resistance to the vaccination.”

The measles outbreak was first reported in Zimbabwe’s Manicaland province, which borders Mozambique, and has since spread nationwide.
…

The death toll from a measles outbreak in Zimbabwe has risen to almost 700 children, the country’s health ministry has said.

Some are calling for the enactment of legislation to make vaccination mandatory in a country where anti-modern medicine religious sects hold sway on large swathes of the population of 15 million people.

The southern African country’s health ministry announced at the weekend that 698 children have died from measles since the outbreak started in April.

The ministry said 37 of the deaths occurred on a single day on Sept. 1. The health ministry said it had recorded 6,291 cases by Sept. 4.

The latest figures are more than four times the number of deaths announced about two weeks ago when the ministry said 157 children, most of whom were unvaccinated due to their family’s religious beliefs, had succumbed to the disease.

Dr. Johannes Marisa, the president of the Medical and Dental Private Practitioners of Zimbabwe Association, told The Associated Press on Monday that the government should escalate an ongoing mass vaccination campaign and embark on awareness programs targeted especially at anti-vaccine religious groups.

“Because of the resistance, education may not be enough so the government should also consider using coercive measures to ensure that no one is allowed to refuse vaccination for their children,” said Marisa. He urged the government to “consider enacting legislation that makes vaccination against killer diseases such as measles mandatory.”

UNICEF on Monday said it “is deeply concerned” with the number of cases and deaths among children due to measles. The agency said it is assisting the government to combat the outbreak through immunization programs.

The measles outbreak was first reported in the eastern Manicaland province in early April and has since spread to all parts of the country.

Many of the deaths have been of children who were not vaccinated, Information Minister Monica Mutsvangwa said in August.

Zimbabwe’s Cabinet has invoked a law used to respond to disasters to deal with the outbreak.

The government has embarked on a mass vaccination campaign targeting children aged between 6 months and 15 years old and is engaging traditional and faith leaders to support the drive.

Zimbabwe continued vaccinating children against measles even during the height of the coronavirus pandemic, but the drive has been hampered by religious groups that preach against vaccines.

The Christian sects are against modern medicine and tell their members to rely on self-proclaimed prophets for healing.

Church gatherings that have resumed following the easing of COVID-19 restrictions have “led to the spread of measles to previously unaffected areas,” said the health ministry in a statement last week.

Measles is among the most infectious diseases in the world and mostly spreads in the air by coughing, sneezing or close contact.

Symptoms include coughing, fever and a skin rash, while the risk of severe measles or dying from complications is high among unvaccinated children.

Outbreaks in unvaccinated and malnourished populations have been known to kill thousands. Scientists estimate that more than 90% of the population needs to be immunized to prevent measles outbreaks.

The World Health Organization in April warned of an increase in measles in vulnerable countries as a result of a disruption of services due to COVID-19.

In July, the United Nations children’s agency, UNICEF, said about 25 million children worldwide have missed out on routine immunizations against common childhood diseases, calling it a “red alert” for child health.
…